Reuters logo
BRIEF-Otsuka and Lundbeck announce top-line results from two phase III clinical trials
May 2, 2017 / 8:40 AM / 7 months ago

BRIEF-Otsuka and Lundbeck announce top-line results from two phase III clinical trials

May 2 (Reuters) - H LUNDBECK A/S

* OTSUKA AND LUNDBECK ANNOUNCE IMPROVEMENT OF AGITATION SYMPTOMS RELATED TO ALZHEIMER’S-TYPE DEMENTIA FOLLOWING TREATMENT WITH BREXPIPRAZOLE RELATIVE TO PLACEBO

* IN BOTH STUDIES, PATIENTS TREATED WITH BREXPIPRAZOLE SHOWED IMPROVEMENTS IN SYMPTOMS OF AGITATION RELATIVE TO PLACEBO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below